Lilian Alcaraz

Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ.

RainDance Technologies, Inc. engages in the development and commercialization of professional laboratory system. It develops and manufactures genomic tools for non-invasive liquid biopsy applications for the research, early detection, treatment of cancer, and inherited and infectious diseases. The company was founded by Andrew Griffiths, Darren R. Link, and Jerome Bibette in 2004 and is headquartered in Billerica, MA.

Ovuline, Inc. designs and develops applications for women?s health. It designed two applications, Ovia Fertility and Ovia Pregnancy, to track women?s fertility and pregnancy and also provide users with a feedback loop for their symptoms. The company was founded by Alex Baron and Paris Wallace in June, 2012 and is headquartered in Boston, MA.

Navitor Pharmaceuticals, Inc. develops medicine for age-related diseases. Its drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. The company was founded by Alan L. Crane, David Sabatini and David Goldfarb and is headquartered in Cambridge, MA.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Quaker Partners Management LP (Quaker Partners Mgmt) is a venture capital subsidiary of Independence Capital Partners Inc founded in 2002 by Ira Mark Lubert and Paul Sherrill Neff. The firm is headquartered in Philadelphia, Pennsylvania.

Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel.

BioRexis Pharmaceutical Corp. provides novel protein and peptide drugs with pharmacology and trans-bodies to replace conventional monoclonal antibodies. The company was founded by Christopher P. Prior, Andrew Turner and David R. King in 2002 and is headquartered in Rosemont, PA.

American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA.

Research!America is a lobbying firm. The non-profit company is based in Alexandria, VA. The CEO of the company is Mary Woolley.

Yale Cancer Center operates as a cancer center. It offers cancer immunology, cancer prevention and control, developmental therapeutics, genomics, genetics and epigenetics, radiobiology and radiotherapy, signal transduction, virus and other infection-associated cancers programs. The company was founded in 1974 and is headquartered in New Haven, CT.

Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom.

Part of Johnson & Johnson, Janssen Research & Development LLC is a company that provides research and development medicines and solutions to other medical needs. The company is based in Raritan, NJ.

Part of Advent Venture Partners LLP, Advent Life Sciences LLP is a venture capital firm for visionary innovators. The company is based in London, UK. Advent Life Sciences has achieved its first discovery milestone in collaboration with Bristol Myers Squibb, and is focused on the journey from innovative science to an approved medicine or product. The British company has a history of delivering value and is one of the leading venture capital firms in the industry.

Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom.

The Wellcome Trust Ltd. (Investment Management) (Wellcome-IM) is the investment management division of The Wellcome Trust Ltd., a politically and financially independent global charitable foundation headquartered in London, UK. The Wellcome Trust was founded in 1936, in accordance with Henry Wellcome’s will, to improve health by supporting scientific research and the study of medicine. Funding for this mission came from the profits of the pharmaceutical business he had built up over 50 years. Wellcome-IM manages The Wellcome Trust.

FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona.

GTX medical BV engages in the development of medical devices for targeted epidural spinal stimulation therapy. The company was founded by Jocelyne Bloch, Sjaak Deckers, and Grégoire Courtine in December 2014 and is headquartered in Eindhoven, the Netherlands.

NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark.

Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA.

Protekt Therapeutics Ltd. operates as a biopharmaceutical company. The firm develop a drug for enhancing the long-term memory of those suffering from mild cognitive impairment. The company is headquartered in Ness Ziona, Israel.

iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland.

Pivot Health Technologies, Inc. provides smoking digital health technology solutions. It offers Pivot, a personal sensor and smoking cessation program that uses an FDA-cleared mobile breath sensor, consumer-grade mobile app, behavioral science, and personal coaching. The company was founded by David S. Utley and is headquartered in Redwood City, CA.

Cedilla Therapeutics, Inc. operats as a biotechnology company. It engages in discovering and exploiting insights into protein stability. The company was founded by Alan D. D?Andrea, Steve Gygi, Matthew P. Jacobson, William G. Kaelin, Jr. and Jack Taunton on September 6, 2017 and is headquartered in Cambridge, MA.

Rutgers Cancer Institute of New Jersey, in partnership with RWJBarnabas Health, is the only National Cancer Institute-designated comprehensive cancer center in New Jersey. Rutgers Cancer Institute has locations in New Brunswick and at University Hospital in Newark, as well as through RWJBarnabas Health facilities. The institute offers advanced cancer treatment options, including bone marrow transplantation, proton therapy, CAR T-cell therapy, and complex surgical procedures. Patients have access to cutting-edge therapies such as precision medicine and immunotherapy, many of which are not widely available. The top cancer researchers and clinicians throughout the state collaborate to apply the latest technologies, therapies, and approaches to improve cancer diagnosis and treatment.

Morgan Stanley Expansion Capital (Morgan Stanley Expansion Capital) is a private equity firm, a subsidiary of Morgan Stanley Investment Management Merchant Banking founded in 1986. The firm is headquartered in Los Angeles, California.

ImmPACT Bio USA, Inc. operates as a cell therapy company. The firm develops potent and selective engineered T-cells for the treatment of solid tumors. The company is headquartered in Camarillo, CA.

Apollo Therapeutics LLP is a British biopharmaceutical company that focuses on translating medical research into medicines. The company is based in Stevenage, UK. The company has a portfolio-model built around a centralized management team of experts in pharmaceutical R&D, manufacturing, commercial strategy, fundraising, and business development. The company's assets are housed in separate wholly-owned subsidiary companies, which incorporate best practices from big pharma and venture capital. The company has a scalable R&D platform for the discovery and development of new medicines, enabled by access to five of the world's leading universities and research institutes. The company was founded in 2015, and the CEO is Richard Mason.

Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation.

A2i Therapeutics Ltd. is an Israeli AI-based drug-design company that aims to develop novel therapeutic modulators of the protein ADAR1, a key element of the innate immune system. The company is a joint venture of the FutuRx Incubator and Atomwise, utilizing the AtomNet® AI platform and FutuRx’s technology to translate extraordinary technologies to life-changing therapies.

Part of Johnson & Johnson, Janssen Global Services LLC develops treatments for patients in therapeutic areas of healthcare. The company is based in Raritan, NJ.